228 related articles for article (PubMed ID: 33225311)
1. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.
Liu Z; Filip I; Gomez K; Engelbrecht D; Meer S; Lalloo PN; Patel P; Perner Y; Zhao J; Wang J; Pasqualucci L; Rabadan R; Willem P
Blood Cancer Discov; 2020 Jul; 1(1):112-125. PubMed ID: 33225311
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract][Full Text] [Related]
3. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
4. The Genomic Landscape of HIV-Associated Plasmablastic Lymphoma.
Küppers R
Blood Cancer Discov; 2020 Jul; 1(1):23-25. PubMed ID: 34661140
[TBL] [Abstract][Full Text] [Related]
5. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
Frontzek F; Staiger AM; Zapukhlyak M; Xu W; Bonzheim I; Borgmann V; Sander P; Baptista MJ; Heming JN; Berning P; Wullenkord R; Erdmann T; Lutz M; Veratti P; Ehrenfeld S; Wienand K; Horn H; Goodlad JR; Wilson MR; Anagnostopoulos I; Lamping M; Gonzalez-Barca E; Climent F; Salar A; Castellvi J; Abrisqueta P; Menarguez J; Aldamiz T; Richter J; Klapper W; Tzankov A; Dirnhofer S; Rosenwald A; Mate JL; Tapia G; Lenz P; Miething C; Hartmann W; Chapuy B; Fend F; Ott G; Navarro JT; Grau M; Lenz G
Nat Commun; 2021 Aug; 12(1):5183. PubMed ID: 34465776
[TBL] [Abstract][Full Text] [Related]
6. Plasmablastic lymphoma: An update.
Bailly J; Jenkins N; Chetty D; Mohamed Z; Verburgh ER; Opie JJ
Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):54-63. PubMed ID: 36074710
[TBL] [Abstract][Full Text] [Related]
7. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
8. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C; Nicolae A; Laurent C; Le Bras F; Haioun C; Fataccioli V; Amara N; Adélaïde J; Guille A; Schiano JM; Tesson B; Traverse-Glehen A; Chenard MP; Mescam L; Moreau A; Chassagne-Clement C; Somja J; Escudié F; André M; Martin N; Lacroix L; Lemonnier F; Hamy AS; Reyal F; Bannier M; Oberic L; Prade N; Frénois FX; Beldi-Ferchiou A; Delfau-Larue MH; Bouabdallah R; Birnbaum D; Brousset P; Xerri L; Gaulard P
Blood; 2020 Jan; 135(5):360-370. PubMed ID: 31774495
[TBL] [Abstract][Full Text] [Related]
9. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.
Leeman-Neill RJ; Soderquist CR; Montanari F; Raciti P; Park D; Radeski D; Mansukhani MM; Murty VV; Hsiao S; Alobeid B; Bhagat G
Haematologica; 2022 Jan; 107(1):201-210. PubMed ID: 33297669
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan.
Chen BJ; Hsieh TH; Yuan CT; Wang RC; Yang CF; Chuang WY; Su YZ; Ho CH; Lin CH; Chuang SS
Pathol Res Pract; 2024 Jan; 253():155059. PubMed ID: 38160484
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
[TBL] [Abstract][Full Text] [Related]
12. Plasmablastic lymphoma: from genetics to treatment.
Frontzek F; Hailfinger S; Lenz G
Leuk Lymphoma; 2023 Apr; 64(4):799-807. PubMed ID: 36577021
[TBL] [Abstract][Full Text] [Related]
13. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E; Ladewig E; Schiavoni G; Penson A; Fortini E; Pettirossi V; Wang Y; Rosseto A; Venanzi A; Vlasevska S; Pacini R; Piattoni S; Tabarrini A; Pucciarini A; Bigerna B; Santi A; Gianni AM; Viviani S; Cabras A; Ascani S; Crescenzi B; Mecucci C; Pasqualucci L; Rabadan R; Falini B
Blood; 2018 May; 131(22):2454-2465. PubMed ID: 29650799
[TBL] [Abstract][Full Text] [Related]
14. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
[TBL] [Abstract][Full Text] [Related]
15. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
[TBL] [Abstract][Full Text] [Related]
16. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
[TBL] [Abstract][Full Text] [Related]
17. Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer.
Bricman L; Yengue P; Miscu C; Junius S; Waignein F; Vandenbulcke JM
Acta Gastroenterol Belg; 2021; 84(4):663-665. PubMed ID: 34965049
[TBL] [Abstract][Full Text] [Related]
18. Relapse of Plasmablastic Lymphoma With Cutaneous Involvement in an Immunocompetent Male.
Shwe S; Sharma AA; Lee BA; Smith JE
Ear Nose Throat J; 2022 Jun; 101(5):NP222-NP225. PubMed ID: 32955361
[TBL] [Abstract][Full Text] [Related]
19. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.
Hansra D; Montague N; Stefanovic A; Akunyili I; Harzand A; Natkunam Y; de la Ossa M; Byrne GE; Lossos IS
Am J Clin Pathol; 2010 Nov; 134(5):710-9. PubMed ID: 20959653
[TBL] [Abstract][Full Text] [Related]
20. Plasmablastic Lymphoma of the Small Intestine in an HIV- and EBV-negative Patient.
Fukuo Y; Shibuya T; Ashizawa K; Ito K; Saeki M; Fukushima H; Takahashi M; Nomura K; Okahara K; Haga K; Akazawa Y; Nomura O; Ogura K; Okubo H; Nagahara A
Intern Med; 2021 Sep; 60(18):2947-2952. PubMed ID: 33776007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
